N. Rejeb

A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors

A. Gianella-Borradori, M. Mita, A. Mita, 2014, Targeted Oncology.

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

E. Raymond, F. Goldwasser, S. Faivre, 2014, Investigational New Drugs.

Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies.

E. Raymond, A. Italiano, S. Faivre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.

G. Martinelli, F. Giles, J. Duyster, 2013, Leukemia research.

Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies

A. Gratwohl, J. Duyster, A. Gianella-Borradori, 2008 .